MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Cisplatin (Platinol ®)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Oncotarget 2017 March [Epub ahead of print] [Link] Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare tumor linked to a dismal prognosis. Even the most effective chemotherapeutical regime of pemetrexed combined with cisplatin leads to a […]

Comments Off on Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Journal of Clinical Oncology 2017 April [Epub ahead of print] [Link] Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW Abstract Purpose Pegylated arginine deiminase (ADI-PEG […]

Comments Off on Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion

Lung Cancer (Netherlands) 2017 February [Epub 2016 December 21] [Link] Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K Abstract OBJECTIVES: Malignant pleural effusion (MPE) has a poor prognosis. Most patients are treated with tube thoracostomy and sclerotherapy, although its success rate is around 64%. We have investigated intrapleural perfusion with hyperthermic […]

Comments Off on Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

International Journal of Oncology 2017 February 9 [Epub ahead of print] [Link] Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O’Byrne KJ, Cuffe S, Finn SP, Gray SG Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the pleura primarily associated with prior exposure to asbestos. The […]

Comments Off on Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases […]

Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 – A Case Report

Cancer & Chemotherapy 2016 November [Link] Miura T, Iida , Igaki , Shiobara H, Matsumoto R, Mitachi K, Miyakawa T, Ohata Y, Saitou K, Irie T, Yamazaki S Abstract Malignant mesothelioma is a rare aggressive solid tumor that is invariably incurable. A 23-year-old female patient with ascites, anemia, and high levels of ferritin and CRP […]

Comments Off on Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 – A Case Report

Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

European Journal of of Radiology [2017 January] [Link] Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T Abstract PURPOSE: Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most […]

Comments Off on Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

New therapeutic strategies for malignant pleural mesothelioma

Biochemical Pharmacology 2017 January [Epub ahead of print] [Link] Bonelli MA, Fumarola C, La Monica S, Alfieri R Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. Therapeutic actions are limited due to the late stage at which most patients are diagnosed and the […]

Comments Off on New therapeutic strategies for malignant pleural mesothelioma

Malignant pleural fluid from mesothelioma has potent biological activities

Respirology 2017 January [Epub 2016 August 25] [Link] Cheah HM, Lansley SM, Varano Della Vergiliana JF, Tan AL, Thomas R, Leong SL, Creaney J, Lee YC Abstract BACKGROUND AND OBJECTIVE: Malignant pleural effusion (MPE) affects >90% of mesothelioma patients. Research on MPE has focused on its physical impact on breathlessness; MPE is rich in growth […]

Comments Off on Malignant pleural fluid from mesothelioma has potent biological activities

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

International Journal of Cancer 2017 January [Epub 2016 September 19] [Link] Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D’Incalci M, Frapolli R Abstract It has recently been reported that a large proportion […]

Comments Off on Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts